title: miRNA in clinical practice: pancreatic cancer.
abstract: To date, pancreatic cancer (PDAC) can't be diagnosed early. Consequently, a majority of patient (80%) display an advanced disease that results in a low resection rate leading to an overall median survival of 4 to 6months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are desperately needed to help alleviate the dismal prognosis of this disease. In this chapter, we review the translational studies demonstrating that miRNAs, alone or in combination, may soon translate into clinical applications as long-awaited screening tools for PDAC.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale INSERM, Centre de Recherche en Cancérologie de Toulouse UMR1037, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Humeau
authors.forename: Jérôme
authors.initials: J
authors.lastname: Torrisani
authors.forename: Pierre
authors.initials: P
authors.lastname: Cordelier
mesh_terms: D000818:Animals; D018572:Disease-Free Survival; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000401:mortality; D012334:RNA, Neoplasm / Q000378:metabolism*; D015996:Survival Rate
chemical_list: D035683:MicroRNAs; D012334:RNA, Neoplasm